Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL; Cancer and Leukemia Group B; Cox NJ, Dolan ME. Wheeler HE, et al. Among authors: njiaju uo. Clin Cancer Res. 2013 Jan 15;19(2):491-9. doi: 10.1158/1078-0432.CCR-12-2618. Epub 2012 Nov 30. Clin Cancer Res. 2013. PMID: 23204130 Free PMC article.
Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study.
Arowolo OA, Njiaju UO, Ogundiran TO, Abidoye O, Lawal OO, Obajimi M, Adetiloye AV, Im HK, Akinkuolie AA, Oluwasola A, Adelusola K, Kayode AA, Agbakwuru AE, Oduntan H, Babalola CP, Fleming G, Olopade OC, Falusi AG, Durosinmi MA, Olopade OI. Arowolo OA, et al. Among authors: njiaju uo. Breast J. 2013 Sep-Oct;19(5):470-7. doi: 10.1111/tbj.12149. Epub 2013 Jul 19. Breast J. 2013. PMID: 23865786 Free PMC article. Clinical Trial.
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ. Burkard ME, et al. Among authors: njiaju uo. Clin Breast Cancer. 2014 Jun;14(3):205-11. doi: 10.1016/j.clbc.2013.10.018. Epub 2013 Oct 26. Clin Breast Cancer. 2014. PMID: 24342730 Free PMC article. Clinical Trial.
11 results